Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/Sirtris_Pharmaceuticals> ?p ?o }
Showing triples 1 to 41 of
41
with 100 triples per page.
- Sirtris_Pharmaceuticals abstract "Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Founded in 2004 by Harvard University biologist David Sinclair, venture capitalist Christoph Westphal, and serial entrepreneur Andrew Perlman, the company went public in 2007 and was subsequently purchased by GlaxoSmithKline in 2008 for $720 million. It was operated as a business unit of GSK until 2013, when it was absorbed into GSK, where research and development continues. Sirtris's drug discovery was focused on developing activators of sirtuins, a class of enzyme that may mediate benefits of calorie restriction. The company's current lead candidates are SRT2104 and SRT2379, which are both potent activators of the SIRT1 enzyme. These and related molecules are in clinical development. The company's other drug candidate was SRT-501, a proprietary formulation of the compound resveratrol, possibly an activator of the SIRT1 enzyme. Development of SRT-501 was halted by GlaxoSmithKline in late 2010, due to suspected drug-related adverse effects in study participants. The company later focused on developing more potent synthetic activators of SIRT1 and is investigating SIRT3 as another potential drug target. Studies from rivals Amgen and Pfizer cast doubt on whether SIRT1 was directly activated. Subsequent work provided evidence that the original conclusions of Sinclair were correct: SIRT1 is directly activated by resveratrol and the synthetic activators, with the activator binding in the N-terminus of SIRT1. A mutation in this N-terminal SIRT1 domain (SIRT1-E230K) was shown to block activation by resveratrol and by synthetic activators from Sirtris, both in vitro and in vivo, largely settling the scientific debate. In 2014, SRT1720 and SRT2104 were shown to extend the health span and the lifespan of mice on a standard diet.".
- Sirtris_Pharmaceuticals wikiPageExternalLink www.genocea.com.
- Sirtris_Pharmaceuticals wikiPageExternalLink www.gsk.com.
- Sirtris_Pharmaceuticals wikiPageExternalLink www.ovascience.com.
- Sirtris_Pharmaceuticals wikiPageID "22733563".
- Sirtris_Pharmaceuticals wikiPageLength "5702".
- Sirtris_Pharmaceuticals wikiPageOutDegree "12".
- Sirtris_Pharmaceuticals wikiPageRevisionID "672756235".
- Sirtris_Pharmaceuticals wikiPageWikiLink Andrew_Perlman.
- Sirtris_Pharmaceuticals wikiPageWikiLink Calorie_restriction.
- Sirtris_Pharmaceuticals wikiPageWikiLink Cambridge,_MA.
- Sirtris_Pharmaceuticals wikiPageWikiLink Cambridge,_Massachusetts.
- Sirtris_Pharmaceuticals wikiPageWikiLink Category:Biotechnology_companies_of_the_United_States.
- Sirtris_Pharmaceuticals wikiPageWikiLink Category:Life_sciences_industry.
- Sirtris_Pharmaceuticals wikiPageWikiLink Christoph_Westphal.
- Sirtris_Pharmaceuticals wikiPageWikiLink David_Sinclair_(biologist).
- Sirtris_Pharmaceuticals wikiPageWikiLink GlaxoSmithKline.
- Sirtris_Pharmaceuticals wikiPageWikiLink Resveratrol.
- Sirtris_Pharmaceuticals wikiPageWikiLink SIRT1.
- Sirtris_Pharmaceuticals wikiPageWikiLink SIRT3.
- Sirtris_Pharmaceuticals wikiPageWikiLink Sirtuin-activating_compound.
- Sirtris_Pharmaceuticals wikiPageWikiLink Sirtuin_1.
- Sirtris_Pharmaceuticals wikiPageWikiLink Sirtuin_activator.
- Sirtris_Pharmaceuticals wikiPageWikiLinkText "Sirtris Pharmaceuticals".
- Sirtris_Pharmaceuticals hasPhotoCollection Sirtris_Pharmaceuticals.
- Sirtris_Pharmaceuticals wikiPageUsesTemplate Template:Notability.
- Sirtris_Pharmaceuticals wikiPageUsesTemplate Template:Reflist.
- Sirtris_Pharmaceuticals subject Category:Biotechnology_companies_of_the_United_States.
- Sirtris_Pharmaceuticals subject Category:Life_sciences_industry.
- Sirtris_Pharmaceuticals type Article.
- Sirtris_Pharmaceuticals type Company.
- Sirtris_Pharmaceuticals type Article.
- Sirtris_Pharmaceuticals type Company.
- Sirtris_Pharmaceuticals comment "Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Founded in 2004 by Harvard University biologist David Sinclair, venture capitalist Christoph Westphal, and serial entrepreneur Andrew Perlman, the company went public in 2007 and was subsequently purchased by GlaxoSmithKline in 2008 for $720 million.".
- Sirtris_Pharmaceuticals label "Sirtris Pharmaceuticals".
- Sirtris_Pharmaceuticals sameAs m.05zk177.
- Sirtris_Pharmaceuticals sameAs Q7530650.
- Sirtris_Pharmaceuticals sameAs Q7530650.
- Sirtris_Pharmaceuticals wasDerivedFrom Sirtris_Pharmaceuticals?oldid=672756235.
- Sirtris_Pharmaceuticals homepage www.gsk.com.
- Sirtris_Pharmaceuticals isPrimaryTopicOf Sirtris_Pharmaceuticals.